Drofenine

Drofenine

SCHEMBL25124

CCN(CC)CCOC(=O)C(c1ccccc1)C1CCCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 8/20 1.00
CHRM1 P11229 8/20 1.00
CYP3A4 P08684 3/20 1.00
LMNA P02545 2/20 1.00
CYP1A2 P05177 2/20 1.00
CYP2D6 P10635 2/20 1.00
HTR1A P08908 1/20 1.00
ADRA2A P08913 1/20 1.00
DRD1 P21728 1/20 1.00
SLC6A2 P23975 1/20 1.00
ADRA1A P35348 1/20 1.00
OPRM1 P35372 1/20 1.00
DRD3 P35462 1/20 1.00
SLC6A3 Q01959 1/20 1.00
KCNH2 Q12809 1/20 1.00
TSHR P16473 1/20 1.00
CHRM3 P20309 7/20 0.63
ALDH1A1 P00352 2/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
CHRM4 P08173 6/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Drofenine SCHEMBL446912 0.99 CYP3A4 (1.00) CHRM2CHRM1CYP3A4LMNACYP1A2
Drofenine SCHEMBL1649803 0.98 CHRM2 (0.95) CHRM2CHRM1CYP3A4LMNACYP1A2
SCHEMBL10955574 0.83 SLC6A2 (0.70) CHRM2CHRM1CYP3A4LMNACYP1A2
SCHEMBL28622583 0.82 SLC6A2 (0.69) CHRM2CHRM1CYP3A4LMNACYP1A2
SCHEMBL7489656 0.81 SLC6A2 (0.68) CHRM2CHRM1CYP3A4LMNACYP1A2
SCHEMBL28632940 0.81 SLC6A2 (0.67) CHRM2CHRM1CYP3A4LMNACYP1A2
SCHEMBL28622638 0.81 SLC6A3 (0.67) CHRM2CHRM1CYP3A4LMNACYP1A2
SCHEMBL28619401 0.80 SLC6A2 (0.66) CHRM2CHRM1CYP3A4LMNACYP1A2
SCHEMBL28637337 0.80 SLC6A2 (0.66) CHRM2CHRM1CYP3A4LMNACYP1A2
SCHEMBL28636471 0.80 SLC6A2 (0.66) CHRM2CHRM1CYP3A4LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 654 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12550885-B2 Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells UNIVERSITY OF CINCINNATI (US) 2026-02-17 US claimed
EP-4658278-A1 SELECTIVE FIASMA TREATMENT Valo Health, Inc. (US) 2025-12-10 EP claimed
WO-2024163699-A1 SELECTIVE FIASMA TREATMENT VALO HEALTH, INC. (US) 2024-08-08 WO claimed
US-20230003721-A1 MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2023-01-05 US claimed
US-20210235686-A1 RED BLOOD CELL STORAGE SOLUTIONS, SOLUTION ADDITIVES, AND METHODS FOR IMPROVING THE STORAGE OF RED BLOOD CELLS UNIVERSITY OF CINCINNATI 2021-08-05 US claimed
US-20210000782-A1 APPLICATION OF DROFENINE OR SALT THEREOF TO PREPARATION OF MEDICINE FOR TREATING PERIPHERAL NEURON AXONAL INJURY AND PERIPHERAL RELATED NEUROPATHY Nanjing University of Chinese Medicine (CN) 2021-01-07 US claimed
CN-109846874-A The application of drofenine and its salt in the drug of the relevant neuropathy in preparation treatment and peripheral neurons axonal injury, periphery 南京中医药大学 2019-06-07 CN claimed
CN-108186622-A The application of drofenine and its pharmaceutically acceptable salt in the drug for treating Alzheimer disease is prepared 南京中医药大学 2018-06-22 CN claimed
US-20150190377-A1 NEURONAL REGENERATION CHILDREN'S MEDICAL CENTER CORPORATION 2015-07-09 US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
EP-1273301-B1 Pharmaceutical preparations based on active ingredients susceptible to illicit administration ALTERGON SA (CH) 2006-09-06 EP claimed
US-20060188445-A1 Assay for compounds that protect against sensory hair cell death and compounds identified by same FRED HUTCHINSON CANCER RESEARCH CENTER 2006-08-24 US claimed
EP-1551370-A1 AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN IDEA AG (DE) 2005-07-13 EP claimed
US-20040105881-A1 Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin IDEA AG (DE) 2004-06-03 US claimed
WO-2004032900-A1 AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN IDEA AG (DE) 2004-04-22 WO claimed
EP-1273301-A2 Pharmaceutical preparations based on active ingredients susceptible to illicit administration ALTERGON S.A. (CH) 2003-01-08 EP claimed
EP-1014943-B1 MEDICAL AEROSOL FORMULATIONS JAGO RES AG (CH) 2002-06-19 EP claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060188445-A1 Assay for compounds that protect against sensory hair cell death and compounds identified by same AIFM1, CASP3, CASP10 CHRM2 4776/4885CHRM1 4794/4885CYP3A4 4822/4885
US-12550885-B2 Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells SMPD3, SMPD4, CMA1 CHRM2 100/4885CHRM1 246/4885CYP3A4 173/4885
US-20210000782-A1 APPLICATION OF DROFENINE OR SALT THEREOF TO PREPARATION OF MEDICINE FOR TREATING PERIPHERAL NEURON AXONAL INJURY AND PERIPHERAL RELATED NEUROPATHY BDNF, PMP22, NGF CHRM2 2627/4885CHRM1 3686/4885CYP3A4 4678/4885
US-20040105881-A1 Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin CUTA, ABCG2, PIGS CHRM2 2986/4885CHRM1 3667/4885CYP3A4 1106/4885
US-20150190377-A1 NEURONAL REGENERATION GAP43, DCX, BDNF CHRM2 4375/4885CHRM1 4780/4885CYP3A4 4880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.